While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.
Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.
Express Scripts and Gilead Sciences are playing a high-priced game of chicken. At stake is the fate of Sovaldi (sofosbuvir), Gilead's high-priced hepatitis C pill, and the future of hep C treatment in the U.S. Not to mention the future of Sovaldi rivals from AbbVie, Bristol-Myers Squibb, and more.
Rep. Henry Waxman and several Democratic colleagues in Congress wrote Gilead CEO John Martin an excoriating letter on Friday, demanding to know why Gilead Sciences' hepatitis C wonder drug Sovaldi costs $84,000--and whether Gilead is doing anything to make sure that poor patients get access to it.
Idenix Pharmaceuticals believes Gilead Sciences violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight into Europe, angling for a cut of sales.
Payers are growing increasingly balky at the price Gilead Sciences slapped on its breakthrough hepatitis C pill Sovaldi. An expert panel in California that assesses new treatments voted Sovaldi a "low value" treatment--not because it doesn't work well enough, but because of its $1,000-a-pill price tag.
India's Ranbaxy Laboratories has issued another recall for its generic Lipitor, but a series of product recalls in recent weeks have come from plants around the world and companies as varied as Pfizer, Mylan and Gilead Sciences.
How can Medicaid pay for the pricey new generation of hepatitis C drugs? Insurers want to know. And they're now asking state health agencies to pitch in, Reuters reports.
Martin's tenure has seen the company build blockbuster revenue from its HIV franchise while creating a new standard of care in the hepatitis C arena.
San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead, planning to launch a Phase III trial on the drug to treat lung infections in cystic fibrosis patients.